Tag: CardioFocus

CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China

– China Grand Pharma will seek regulatory approvals and commercialize CardioFocus’ innovative catheter ablation technology for pulmonary vein isolation – Pulmonary vein isolation is the gold standard treatment for atrial fibrillation MARLBOROUGH, Mass., June 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device […]

CardioFocus Announces The Publication Of HeartLight X3 Pivotal Study Data

HeartLight® X3 System Has Significantly Shorter Procedure Times for Atrial Fibrillation Ablation MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were […]

CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal

MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal. “We are pleased to be […]

CardioFocus® Announces Initial Commercial Procedures Following US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc. today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight® X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation (AFib), the […]